ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.PLoS neglected tropical diseases · 2021Trial
- Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Article
- Exploring the landscape of lymphatic filariasis research in India: A scientometric analysis of two decades from 2000 to 2024.PLoS neglected tropical diseases · 2026Article
- Microplanning improves stakeholders' perceived capacity and engagement to implement lymphatic filariasis mass drug administration.PLoS neglected tropical diseases · 2025Article
- Persons 'never treated' in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020-2021.International health · 2024Article
- How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Subnational Projections of Lymphatic Filariasis Elimination Targets in Ethiopia to Support National Level Policy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- An Ensemble Framework for Projecting the Impact of Lymphatic Filariasis Interventions Across Sub-Saharan Africa at a Fine Spatial Scale.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Diethylcarbamazine elicits CaAntimicrobial agents and chemotherapy · 2023Article
- Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa.PLoS neglected tropical diseases · 2023Article
- [Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].Medecine tropicale et sante internationale · 2022Article
- Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study.The Lancet. Global health · 2022Article
- Statistical methods for linking geostatistical maps and transmission models: Application to lymphatic filariasis in East Africa.Spatial and spatio-temporal epidemiology · 2022Article
- The relevance of studying insect-nematode interactions for human disease.Pathogens and global health · 2022Article
- Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside.International journal for parasitology. Drugs and drug resistance · 2021Article
- Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia.The American journal of tropical medicine and hygiene · 2021Article
- How should Indonesia consider its neglected tropical diseases in the COVID-19 era? Hopes and challenges (Review).Biomedical reports · 2021Review
- The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the 2020 target year for elimination of lymphatic filariasis (LF) approaching, there is an urgent need to assess how long mass drug administration (MDA) programs with annual ivermectin + albendazole (IA) or diethylcarbamazine + albendazole (DA) would still have to be continued, and how elimination can be accelerated. We addressed this using mathematical modeling. Methods: We used 3 structurally different mathematical models for LF transmission (EPIFIL, LYMFASIM, TRANSFIL) to simulate trends in microfilariae (mf) prevalence for a range of endemic settings, both for the current annual MDA strategy and alternative strategies, assessing the required duration to bring mf prevalence below the critical threshold of 1%. Results: Three annual MDA rounds with IA or DA and good coverage (≥65%) are sufficient to reach the threshold in settings that are currently at mf prevalence <4%, but the required duration increases with increasing mf prevalence. Switching to biannual MDA or employing triple-drug therapy (ivermectin, diethylcarbamazine, and albendazole [IDA]) could reduce program duration by about one-third. Optimization of coverage reduces the time to elimination and is particularly important for settings with a history of poorly implemented MDA (low coverage, high systematic noncompliance). Conclusions: Modeling suggests that, in several settings, current annual MDA strategies will be insufficient to achieve the 2020 LF elimination targets, and programs could consider policy adjustment to accelerate, guided by recent monitoring and evaluation data. Biannual treatment and IDA hold promise in reducing program duration, provided that coverage is good, but their efficacy remains to be confirmed by more extensive field studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.